Jennifer Doudna, Intellia co-founder (Susan Walsh/AP Images)
February 28, 2022 04:01 PM ESTUpdated 04:26 PM
R&D
Cell/Gene Tx

Ex­pand­ed In­tel­lia CRISPR da­ta set up show­down with Pfiz­er, Io­n­is and Al­ny­lam in not-so-rare dis­ease

Jason Mast

Editor

Eight months af­ter de­liv­er­ing land­mark re­sults with one of the first CRISPR clin­i­cal tri­als of its kind, In­tel­lia an­nounced the ex­per­i­men­tal ther­a­py held up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Com­pounders sue FDA over re­moval of semaglu­tide from of­fi­cial short­age list

Al­ny­lam eyes big­ger dis­eases in more tis­sue types at ‘in­flec­tion point’ for siR­NA

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times